The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.9M data for 1.2M Compounds and 9.3K Targets. Of those, 1,359K data for 631K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

30 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

Article Title
Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands.EBI
Comenius University In Bratislava
Novel GSK-3 inhibitors with improved cellular activity.EBI
Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors.EBI
Paris-Sud University
Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease.EBI
Central University
Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors.EBI
Vertex Pharmaceuticals
The design and synthesis of potent and selective inhibitors of Trypanosoma brucei glycogen synthase kinase 3 for the treatment of human african trypanosomiasis.EBI
University of Dundee
Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase.EBI
Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors.EBI
Roche Research Center
Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.EBI
The Repertoire of Small-Molecule PET Probes for Neuroinflammation Imaging: Challenges and Opportunities beyond TSPO.EBI
Massachusetts General Hospital
Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship.EBI
Zunyi Medical University
Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.EBI
Hefei University of Technology
(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.EBI
Johnson & Johnson Pharmaceutical Research and Development
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.EBI
Hefei University of Technology
Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review.EBI
University of Louisiana At Lafayette
A critical update on the strategies towards small molecule inhibitors targeting Serine/arginine-rich (SR) proteins and Serine/arginine-rich proteins related kinases in alternative splicing.EBI
China Pharmaceutical University
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.EBI
The First Affiliated Hospital of Zhengzhou University
Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases.EBI
Insights into the chemistry and therapeutic potential of furanones: A versatile pharmacophore.EBI
Jamia Hamdard
1-Aryl-3-(4-methoxybenzyl)ureas as potentially irreversible glycogen synthase kinase 3 inhibitors: Synthesis and biological evaluation.EBI
Stellenbosch University
Synthesis and evaluation of 8-amino-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives as glycogen synthase kinase-3 (GSK-3) inhibitors.EBI
Jeil Pharmaceutical
CH...O and CH...N hydrogen bonds in ligand design: a novel quinazolin-4-ylthiazol-2-ylamine protein kinase inhibitor.EBI
Vertex Pharmaceuticals
The development of potent and selective bisarylmaleimide GSK3 inhibitors.EBI
Lilly Research Laboratories
3D QSAR studies on GSK-3 inhibition by aloisines.EBI
Zhejiang University
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.EBI
Seoul National University
Natural and synthetic bioactive inhibitors of glycogen synthase kinase.EBI
Jamia Hamdard (Hamdard University)